Skip to main content
SpringerLink
Log in

The PROTAC gold rush

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Schematic of proteolysis-targeting chimera (PROTAC) degraders.

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan, USA

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. The PROTAC gold rush. Nat Biotechnol 40, 12–16 (2022). https://doi.org/10.1038/s41587-021-01173-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-021-01173-2

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation